How has been the historical performance of Bafna Pharma.?

Answer:Bafna Pharma has experienced a significant decline in its financial performance over the years, particularly from 2015 to 2019. Net sales decreased from 97.67 Cr in March 2015 to 43.36 Cr in March 2019. The total operating income followed a similar trend, dropping from 138.79 Cr in March 2015 to 43.36 Cr in March 2019. The company's operating profit (PBDIT) also turned negative, going from a profit of 28.35 Cr in March 2015 to a loss of 12.69 Cr in March 2019. This decline is reflected in the profit before tax, which fell from a profit of 6.07 Cr in March 2015 to a loss of 17.28 Cr in March 2019. Consequently, the profit after tax showed a similar downward trajectory, moving from a profit of 6.22 Cr in March 2015 to a loss of 18.35 Cr in March 2019. The earnings per share (EPS) also worsened, going from 3.31 in March 2015 to -7.98 in March 2019. The company's total assets decreased from 199.83 Cr in March 2015 to 71.31 Cr in March 2020, while total liabilities also fell from 199.83 Cr to 71.31 Cr during the same period. Cash flow from operating activities turned negative, with a cash outflow of 34.00 Cr in March 2020 compared to a cash inflow of 10.66 Cr in March 2015.

Breakdown:
Bafna Pharma's financial performance has shown a consistent decline over the years, particularly from 2015 to 2019. The net sales dropped significantly from 97.67 Cr in March 2015 to 43.36 Cr in March 2019, while total operating income decreased from 138.79 Cr to the same figure of 43.36 Cr. The operating profit transitioned from a positive 28.35 Cr in March 2015 to a negative 12.69 Cr by March 2019, indicating a severe downturn in profitability. This trend continued with profit before tax, which fell from 6.07 Cr to -17.28 Cr, and profit after tax, which decreased from 6.22 Cr to -18.35 Cr. The earnings per share reflected this decline, moving from 3.31 to -7.98. Furthermore, total assets decreased from 199.83 Cr in March 2015 to 71.31 Cr in March 2020, alongside total liabilities, which also declined from 199.83 Cr to 71.31 Cr. The cash flow from operating activities turned negative, showing a cash outflow of 34.00 Cr in March 2020, compared to a cash inflow of 10.66 Cr in March 2015, highlighting the company's deteriorating financial health.